Newer antidepressant drug use in East Asian psychiatric treatment settings: REAP (Research on East Asia Psychotropic Prescriptions) Study

Harvard University, Cambridge, Massachusetts, United States
British Journal of Clinical Pharmacology (Impact Factor: 3.69). 04/2007; 63(4):431-7. DOI: 10.1111/j.1365-2125.2006.02780.x
Source: PubMed

ABSTRACT Antidepressant use in East Asia is poorly documented. We compared patients given newer and older antidepressants to test the hypothesis, suggested in the literature, that use of newer antidepressants is associated with treatment settings rather than specific diagnostic categories.
We compared rates of use of older (pre1990) vs. newer antidepressants among 1898 patients identified as antidepressant treated at 21 centres in five East Asian countries (China, Japan, Korea, Singapore, Taiwan) in 2003. Demographics, treatment setting and clinical factors associated with preferential use of newer drugs were tested in univariate and multivariate analyses.
Newer antidepressants were included in the treatment regimens of 67.5% (N = 1282/1898) of study subjects. Prescription for newer antidepressants was significantly associated with younger age (z = -4.55, d.f. = 1888, P < 0.001), hospitalization [odds ratio (OR) 1.32, 95% confidence interval (CI) 1.07, 1.64, P < 0.01] and treatment within psychiatric hospitals (OR 1.59, 95% CI 1.27, 2.00, P < 0.001). On multivariate analyses, treatment with newer antidepressants was independently associated with younger age (P < 0.001), country (P < 0.001) and treatment within private hospitals (P < 0.001), but not with sex or diagnosis of affective or anxiety disorders (all P > 0.1).
Demographic factors and treatment settings appear to influence antidepressant choice more than clinical factors such as diagnosis.

Download full-text


Available from: Norman Sartorius, Aug 17, 2015
  • [Show abstract] [Hide abstract]
    ABSTRACT: The present review focuses on the pharmacoepidemiological issues of psychotropic drug use in countries within east Asia, with special emphasis on antipsychotic, antidepressant and benzodiazepine prescriptions. Pharmacogenetic studies in different ethnic groups are also reviewed. Recent studies have revealed the prevalence of antipsychotic polytherapy (defined as the use of more than one antipsychotic; up to 45.7%), less conservative antipsychotic use (defined as the use of more than 1000 mg/day chlorpromazine equivalents; up to 17.9%) and depot antipsychotic use (up to 15.3%) in different populations in east Asia. Clozapine is commonly prescribed (up to 60%) in China. There is a trend of increasing second-generation antipsychotic use in east Asian countries. Up to 67.5% of patients received newer antidepressants such as selective serotonin reuptake inhibitors. Benzodiazepine medications are used in up to 29.9% of study populations. Socioeconomic factors appear to be one of the major common factors that affect the prescription of antipsychotics and newer antidepressants. Pharmacogenetic factors associated with antipsychotic response, weight gain and extrapyramidal side effects have been examined. Treatment adherence and pharmacoeconomic factors are relatively understudied. Future studies on prescribing trends of antipsychotics and antidepressants need to focus on children, adolescent and elderly patient populations, the impact of changing prescription trends and the long-term effects on patients and their caregivers, as well as pharmacogenetic factors, which can potentially pave the way for better and more individualized prescription of psychotropic drugs in east Asia.
    Current opinion in psychiatry 12/2008; 21(6):645-50. DOI:10.1097/YCO.0b013e32830e6dc4 · 3.55 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: A multi-environment turbulent combustion model, originally developed for Reynolds averaged Navier–Stokes equations (RANS), was extended to large eddy simulation (LES) and was used to model a bluff-body stabilized flame series (HM1 and HM3) that ranges from near equilibrium to near global extinction. The multi-environment filtered density function model (MEFDF) depicts the filtered density function (FDF) as a weighted summation of a small number of multi-dimensional Dirac delta functions in composition space. It is derived from the transport FDF equation using the direct quadrature method of moments (DQMOM). The MEFDF method with multiple reactive scalars retains the unique property of the joint FDF model of treating the chemical source term exactly. It was coupled with a 19-species reduced mechanism based on quasi-steady-state assumption and an In Situ adaptive tabulation (ISAT) algorithm for chemical source term integration. The model successfully captures the level of local extinction of the two flames exhibited in experiment. The predicted radial profiles of mixture fraction, temperature and CO mass fraction are in good agreement with measurements. The current work highlights the potential of LES/MEFDF approach as a tool for modeling of turbulent flame stability and combustion dynamics as well as pollutant emissions.
    Proceedings of the Combustion Institute 01/2011; 33(1):1347-1353. DOI:10.1016/j.proci.2010.07.005 · 3.83 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: This systematic review evaluated Chinese trials examining the efficacy of venlafaxine in the treatment of depression. Chinese databases CNKI and VIP and western databases were searched for blinded randomized controlled trial publications comparing venlafaxine to other antidepressants or placebo (in English or Chinese). Trials had to establish diagnosis of depression according to the Chinese Classification of Mental Disorders, Diagnostic and Statistical Manual of Mental Disorders, or International Classification of Diseases. Studies were excluded if more than 20% of participants had a primary diagnosis of dysthymia or if more than 15% had a primary diagnosis of bipolar disorder. Effect sizes were calculated as Hedges' g for rating scale scores and Mantel-Haenszel risk ratios (MH RR) for response and remission data. Effect sizes were combined in a fixed-effects model. A total of 25 studies were included. Nine trials compared venlafaxine to selective serotonin reuptake inhibitor; placebo-controlled trials were lacking. Quality was at best modest, and all trials were underpowered. There were more responders (MH RR, 1.08; 95% confidence interval [CI], 1.02-1.15) and remitters (MH RR, 1.12; 95% CI, 1.02-1.24) in venlafaxine groups compared with those in tricyclic antidepressant group. Hamilton Depression Rating Scale end point scores in the venlafaxine groups were lower (Hedges' g = 0.16; 95% CI, 0.04-0.27), and venlafaxine was better tolerated than tricyclic antidepressant (Hedges' g = 0.56; 95% CI, 0.37-0.74). There were no significant differences between venlafaxine and selective serotonin reuptake inhibitor on any of these parameters. Analyses of publication bias were inconclusive. Chinese researchers have published a number of randomized controlled trials comparing venlafaxine to active comparators, but study quality was found to be low. To make optimal use of their research potential Chinese, researchers will have to improve trial reporting and the peer-review process.
    Journal of clinical psychopharmacology 02/2011; 31(2):194-200. DOI:10.1097/JCP.0b013e31820f932a · 3.76 Impact Factor
Show more